Physician profile
Roberto Wayhs
NPI 1760430458
$10,143.59
in general payments reported to CMS, 2019-2025
41 companies · $1,109 in 2025
The $1,109 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,715 · 2020: $1,004 · 2021: $1,670 · 2022: $1,816 · 2023: $1,523 · 2024: $1,308 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,939.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,151.93 | 2020-2025 | Gallant, Jot Dx, Xience Skypoint |
| Amgen INC. | $1,142.34 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,010.14 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $862.97 | 2019-2025 | Farxiga |
| Medtronic Vascular, INC. | $835.75 | 2019-2020 | |
| Amarin Pharma, INC. | $795.63 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $610.46 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $490.34 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $476.38 | 2021-2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $333.22 | 2024-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $298.05 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $270.28 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.41 | 2019-2025 | Jardiance |
| Pfizer INC. | $207.18 | 2019-2025 | |
| Medtronic, INC. | $175.70 | 2021-2025 | Linq II, Cobalt Dr Mri Surescan |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $144.77 | 2019-2024 | Recross, Nhancer Rx |
| Chiesi USA, INC. | $127.57 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $122.78 | 2022 | |
| Philips North America LLC | $106.87 | 2020-2025 | Extended Holter, (Ck7) Extended Holter, (Ck4) Mcot |
| Boston Scientific Corporation | $92.16 | 2019-2023 | Watchman |
| Irhythm Technologies, INC. | $80.23 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $62.45 | 2019-2022 | |
| Baxter Healthcare | $49.82 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Itamar Medical INC | $44.04 | 2025 | Watchpatone |
| Biosense Webster, INC. | $42.66 | 2024 | Carto 3 |
| Sanofi-Aventis U.S. LLC | $39.35 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $37.64 | 2019 | |
| Abiomed | $36.24 | 2024 | Impella |
| Cardiva Medical, INC. | $31.07 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Arbor Pharmaceuticals, INC. | $30.47 | 2019-2021 | |
| Ethicon US, LLC | $27.33 | 2022 | |
| Terumo Medical Corporation | $22.32 | 2022 | |
| Edwards Lifesciences Corporation | $20.06 | 2022 | |
| Acacia Pharma INC | $17.89 | 2021 | |
| Gilead Sciences, INC. | $16.57 | 2019 | |
| Teleflex LLC | $15.45 | 2022 | |
| Portola Pharmaceuticals, LLC | $15.05 | 2019 | |
| Shockwave Medical, INC | $14.77 | 2022 | |
| Lilly USA, LLC | $13.84 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.06 | 2021 | |
| Cvrx, INC. | $12.35 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Wayhs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.